Lobe Sciences Ltd (LOBE.CX)
0.015
0.00 (0.00%)
CAD |
CNSX |
Nov 21, 16:00
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 2.573M |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | -25.00% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | -- |
Price to Book Value | -- |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | -- |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 99.40% |
Profile
Lobe Sciences LtdĀ is a biopharmaceutical company committed to discovering and developing patient-focused medicines for orphan and rare diseases. It is engaged in drug research and development to improve brain and mental health and wellness. The company plans to commercialize a medical food named Altemia for the treatment of Sickle Cell Disease and has other drugs in pipeline such as L-130 Treatment for Chronic Cluster Headache, L-131 Treatment for Pediatric Anxiety and S-100 Treatment for Sickle Cell Disease. |
URL | https://www.lobesciences.com |
Investor Relations URL | N/A |
HQ State/Province | British Columbia |
Sector | |
Industry | |
Equity Style | Small Cap/Value |
Next Earnings Release | Jan. 31, 2025 (est.) |
Last Earnings Release | Jul. 26, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
Lobe Sciences LtdĀ is a biopharmaceutical company committed to discovering and developing patient-focused medicines for orphan and rare diseases. It is engaged in drug research and development to improve brain and mental health and wellness. The company plans to commercialize a medical food named Altemia for the treatment of Sickle Cell Disease and has other drugs in pipeline such as L-130 Treatment for Chronic Cluster Headache, L-131 Treatment for Pediatric Anxiety and S-100 Treatment for Sickle Cell Disease. |
URL | https://www.lobesciences.com |
Investor Relations URL | N/A |
HQ State/Province | British Columbia |
Sector | |
Industry | |
Equity Style | Small Cap/Value |
Next Earnings Release | Jan. 31, 2025 (est.) |
Last Earnings Release | Jul. 26, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |